4.71
price up icon0.43%   0.02
after-market 시간 외 거래: 4.72 0.010 +0.21%
loading
전일 마감가:
$4.69
열려 있는:
$4.51
하루 거래량:
78,729
Relative Volume:
0.17
시가총액:
$49.37M
수익:
$52.29M
순이익/손실:
$-73.52M
주가수익비율:
-7.1364
EPS:
-0.66
순현금흐름:
$-100.45M
1주 성능:
+3.74%
1개월 성능:
-5.80%
6개월 성능:
-50.58%
1년 성능:
-69.49%
1일 변동 폭
Value
$4.51
$4.79
1주일 범위
Value
$4.25
$4.99
52주 변동 폭
Value
$3.61
$15.33

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
명칭
Precision Biosciences Inc
Name
전화
919-314-5512
Name
주소
302 EAST PETTIGREW STREET, DURHAM, NC
Name
직원
0
Name
트위터
@PrecisionBioSci
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
DTIL's Discussions on Twitter

DTIL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
DTIL
Precision Biosciences Inc
4.71 49.37M 52.29M -73.52M -100.45M -0.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-10 업그레이드 BMO Capital Markets Market Perform → Outperform
2024-04-30 개시 Guggenheim Buy
2022-06-17 개시 BMO Capital Markets Outperform
2022-06-09 다운그레이드 William Blair Outperform → Mkt Perform
2020-07-27 재개 BTIG Research Buy
2020-04-03 다운그레이드 Goldman Buy → Neutral
2020-03-05 개시 Stifel Buy
2020-02-25 개시 William Blair Outperform
2019-08-09 개시 BTIG Research Buy
2019-07-16 개시 H.C. Wainwright Buy
2019-04-22 개시 Barclays Overweight
2019-04-22 개시 Goldman Buy
2019-04-22 개시 JP Morgan Overweight
2019-04-22 개시 Jefferies Buy
모두보기

Precision Biosciences Inc 주식(DTIL)의 최신 뉴스

pulisher
Apr 01, 2025

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace

Apr 01, 2025
pulisher
Apr 01, 2025

Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India

Mar 28, 2025
pulisher
Mar 27, 2025

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer

Mar 27, 2025
pulisher
Mar 26, 2025

Precision BioSciences Reports Positive 2024 Financial Results - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc Q4 Sales Decline - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Precision Biosciences CEO sells $5,359 in stock - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire

Mar 25, 2025
pulisher
Mar 23, 2025

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 23, 2025

Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com

Mar 23, 2025
pulisher
Mar 21, 2025

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace

Mar 21, 2025
pulisher
Mar 21, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire

Mar 21, 2025
pulisher
Mar 21, 2025

Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - StockTitan

Mar 21, 2025
pulisher
Mar 20, 2025

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains $60 target on Precision BioSciences stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus EliminationKey Trial Updates - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Precision Bio rises after gene editing data: BMO upgrades (update) - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Assessing Precision BioSciences: Insights From 4 Financial Analysts - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

FDA Clears First-Ever In Vivo Gene-Editing Trial for Chronic Hepatitis B in the United States - CRISPR Medicine News

Mar 19, 2025
pulisher
Mar 19, 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - 01Net

Mar 19, 2025
pulisher
Mar 19, 2025

Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - StockTitan

Mar 19, 2025
pulisher
Mar 17, 2025

Precision BioSciences' IND Application For PBGENE-HBV Gets FDA Clearance; Stock Climbs - RTTNews

Mar 17, 2025
pulisher
Mar 17, 2025

Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance - MarketScreener

Mar 17, 2025
pulisher
Mar 17, 2025

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts

Mar 17, 2025
pulisher
Mar 17, 2025

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - BioSpace

Mar 17, 2025
pulisher
Mar 15, 2025

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha

Mar 15, 2025
pulisher
Mar 06, 2025

(DTIL) Trading Advice - Stock Traders Daily

Mar 06, 2025

Precision Biosciences Inc (DTIL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):